Furuya, YoichiMullbacher, ArnoPardo, Julian2024-10-042024-10-042076-0817https://hdl.handle.net/1885/733721264Despite accumulating preclinical data demonstrating a crucial role of cytotoxic T cell immunity during viral infections, ongoing efforts on developing COVID-19 vaccines are mostly focused on antibodies. In this commentary article, we discuss potential benefits of cytotoxic T cells in providing long-term protection against COVID-19. Further, we propose that gamma-ray irradiation, which is a previously tested inactivation method, may be utilized to prepare an experimental COVID-19 vaccine that can provide balanced immunity involving both B and T cells.Y.F. is supported by American Heart Association Scientist Development Grant (17SDG33630188) and NIH (1R56AI146434-01). J.P. is supported by Health Institute Carlos III (Fondo-COVID19); Ministry of Science, Innovation, and Universities (SAF2017-83120-C2-1-R); and by Aragon Government (Group B29_17R).application/pdfen-AU© 2020 by the authors. Licensee MDPI, Basel, Switzerland.http://creativecommons.org/licenses/by/4.0/SARS-CoV-2COVID-19Gamma-rayirradiated vaccine202010.3390/pathogens91109282024-03-03Creative Commons Attribution 4.0 International License